People who eat a high-fiber diet or increase their fiber intake after a colon cancer diagnosis may be less likely to die of these tumors than individuals who don’t consume much fiber. READ MORE
Important factors to consider when developing a clinical pathway for colorectal cancer.
Chemoradiotherapy and post-operative chemotherapy may be equally effective when treating patients with gastric cancer.
Lymph node ratio may be a significant indicator of prognosis in patients with rectal cancer and could be used to better stratify patients in trials.
The physical location of a primary tumor may be an indicator of survivor in patients with metastatic colorectal cancer.
Sequencing cell-free DNA may be able to provide baseline information on actionable mutations and improve the quality of care in colorectal cancer.
A re-analysis of 2016 data from the USPSTF on colorectal cancer screening indicates that flexible sigmoidoscopy reduces the risk of death.
Systemic inflammation combined with sarcopenia could double the risk of death in patients with colorectal cancer, suggesting that these markers have clinical predictive value.
For patients with complications after colorectal surgery, being readmitted to the same medical center and being cared for by the surgeon who performed the operation may increase the likelihood of survival.
Research in Review
Patients with rectal cancer who undergo first-line chemotherapy and radiation have lower risk of recurrence and higher rates of survival regardless of whether they choose to have surgery.
Patients with a specific type of metastatic colorectal cancer who are chemotherapy-resistant benefit from treatment with a gene-targeting regimen.
Short-course preoperative radiotherapy combined with delayed surgery reduces the adverse effects of rectal cancer surgery while maintaining its efficiency, according to a study published in The Lancet (published online February 9, 2017; doi: 10.1016/S1470-2045(17)30086-4).
Chemotherapy may be overused among young and middle-aged patients with colon cancer.